Experimental combo for tough leukemia shows promise in early trial
NCT ID NCT05780879
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested adding the targeted drug venetoclax to standard chemotherapy (FLAG or CLAG) for people with newly diagnosed secondary acute myeloid leukemia (sAML), a challenging blood cancer. The goal was to see if the combination could improve complete remission rates. Only 10 participants were enrolled before the study was terminated, so the results are very preliminary and not enough to draw firm conclusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax (a targeted drug) combined with standard chemotherapy (FLAG or CLAG)
What this could lead to
If successful, this combination could improve remission rates for people with secondary acute myeloid leukemia, a hard-to-treat blood cancer.
What could go wrong
This was a very small pilot study (only 10 participants) that was terminated early, so results are limited and may not apply broadly. The combination also carries risks of serious side effects from chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States